【Brand Honors】
1. China Resources Sanjiu won the "China Green Efficiency Enterprise-Green Responsibility Award"
On January 13, CR Sanjiu won the "China Green Efficiency Enterprise-Green Responsibility Award" at the 6th World Environmental Protection Conference.
2. China Resources Sanjiu entered the list of 222 Chinese A-share companies in MSCI
On June 21, China Resources Sanjiu (000999) entered the list of 222 Chinese A-share companies in MSCI, which is a recognition of the overall strength and value of listed companies.
3. Ganmaoling granules/capsules ranked No. 1 in the comprehensive statistical ranking of non-prescription drug products in China (Chinese patent medicine) in the cold and cough category
On December 9, 999 Ganmaoling Granules/Capsules once again won the first place in the “Comprehensive Statistical Ranking of Non-prescription Drug Products in China (Chinese Proprietary Medicine)” in the cold and cough category, winning this honor for eight consecutive years. In addition, 13 varieties of China Resources Sanjiu were selected into the "Comprehensive Ranking of Non-prescription Drug Products in China (Chinese Patent Medicine/Chemical Medicine) List".
【Merger and Acquisition Integration】
1. China Resources Sanjiu acquired 65% equity of Shandong Shenghai to help the development of big health business
On September 13, China Resources Sanjiu officially acquired a 65% stake in Shandong Shenghai. It will help China Resources Sanjiu quickly supplement the categories and varieties of mainstream health care products and build a foundation for the development of the big health business. Shandong Shenghai's good health care product supply chain foundation will help the rapid growth of China Resources Sanjiu's major health business.
2. China Resources Sanjiu acquired 65% equity of Jinfukang Pharmaceutical Co., Ltd. to enrich the anti-tumor product line
On January 17, China Resources Sanjiu acquired a 65% stake in Jilin Jinfukang Pharmaceutical Co., Ltd. ("Jinfukang Pharmaceutical") held by Jilin Donglang Pharmaceutical Co., Ltd. ("Donglang Pharmaceutical"). Further enrich the anti-tumor product line, give full play to the core advantages, and implement the company's business development strategy.
【innovating】
1. The related research project of "Li Wei Wang" won the first prize of Science and Technology Award of China Association of Traditional Chinese Medicine
In March, in the 2016 China Association of Traditional Chinese Medicine Science and Technology Award review, the Institute of Medicinal Plants, Chinese Academy of Medical Sciences was the lead unit, and Kunming Shenghuo Pharmaceuticals was the research project of the participating unit——"Comprehensive Development of Large Varieties of Chinese Medicine Notoginseng Key Technology Creation and Industrialization Application" won the first prize and was voted unanimously, ranking first.
2. "Haowawa Children's Medicine and Health Products Research Center" was established
On December 30, "Haowawa Children's Medicine and Health Products Research Center" was officially established in Sunstone (Tangshan) Pharmaceutical Co., Ltd. This is a new starting point for the development of China Resources Sanjiu's pediatric products, which will effectively promote the development of Sunstone Pharmaceuticals and the upgrade of the Haowall brand.
【governmental support】
1. China Resources Sanjiu participated in the construction of the Sinopharm Seed Seedling Breeding Base and passed the acceptance
On December 1, the Ya'an main base of the national essential medicine seedling breeding (Sichuan) base successfully passed the on-site acceptance of the State Administration of Traditional Chinese Medicine.
The Ya'an main base of the base is jointly established by the Sichuan Academy of Traditional Chinese Medicine, China Resources Sanjiu (Ya'an) Pharmaceutical Co., Ltd. and the Ya'an Municipal People's Government. Breeding technology research and production demonstration and promotion base.
【business development】
1. China Resources Sanjiu formally established the Great Health Division
On the morning of March 7, the business start-up meeting of China Resources Sanjiu Health Division was held. At the meeting, a special start-up ceremony was held. A total of more than 120 people from the company's management and representatives from various departments gathered together to witness the new and promising journey of the Great Health Division.
2. China Resources Sanjiu's fifth-generation cephalosporin antibiotic project settled in Xinmin, Liaoning
On December 19, Xinmin Municipal Government of Liaoning Province and China Resources Jiuxin Pharmaceutical Co., Ltd., a subsidiary of China Resources Sanjiu, signed a cooperation agreement on the production and settlement of its patented product, the fifth-generation cephalosporin antibiotic (cefabiroxetil). The project settled in Shenyang Sanjiu Pharmaceutical Co., Ltd. located in Xinmin Economic Development Zone. After completion, Shenyang Sanjiu Pharmaceutical Co., Ltd. will become the only supplier of the fifth-generation cephalosporin in mainland China.
【Important item】
1. China Resources Sanjiu signed a contract with Hubei Provincial Hospital of Traditional Chinese Medicine on the "Investment and Operation Cooperation Project of Preparation Center in Wudong Campus"
New progress has been made in the strategic cooperation between China Resources Sanjiu Pharmaceutical Co., Ltd. and Hubei Provincial Hospital of Traditional Chinese Medicine. On June 23, the cooperation project of "Investment and Operation of Preparation Center Construction in Wudong Campus" was signed.
2. China Resources Sanjiu signed a strategic framework agreement with Hebei Provincial Hospital of Traditional Chinese Medicine
On August 23, China Resources Sanjiu Pharmaceutical Co., Ltd. signed a strategic framework agreement with Hebei Provincial Hospital of Traditional Chinese Medicine. The two parties will work together to vigorously promote the "Innovative Development of Traditional Chinese Medicine" project.
3. China Resources Sanjiu signed a contract with Anhui University of Traditional Chinese Medicine on the "Industry-University-Research Cooperation Project"
On September 30, China Resources Sanjiu Pharmaceutical Co., Ltd. signed a strategic framework agreement and a scholarship project cooperation agreement with Anhui University of Traditional Chinese Medicine.
【Foreign Cooperation】
1. The cooperation project between China Resources Sanjiu and Sanofi is progressing smoothly
On June 10, Jiao Yanlong, secretary of the Tangshan Municipal Party Committee, visited Sunstone (Tangshan) Pharmaceutical Co., Ltd., learned about the situation after the establishment of the joint venture company, and fully affirmed it. Sunstone Pharmaceuticals is a cooperation project between China Resources Sanjiu and Sanofi, and the cooperation between the two parties is progressing smoothly. At the same time, Yishanfu, the global leading brand of liver-protecting OTC drugs, was handed over smoothly, and the hospital market and retail market achieved expected growth.
2. China Resources Jiuxin and Switzerland's Basilea reached a technology authorization agreement for the fifth generation of cephalosporin antibiotics
On September 28, Shenzhen China Resources Jiuxin Pharmaceutical Co., Ltd. signed an agreement with Basilea Pharmaceutica International Ltd (BSLN), a Swiss listed company, to reach an agreement in mainland China and Hong Kong for the fifth-generation cephalosporin antibiotic (cefebiroxil) under the patent of Basilea. , Macau's exclusive technology authorization cooperation.
1. China Resources Sanjiu won the "China Green Efficiency Enterprise-Green Responsibility Award"
On January 13, CR Sanjiu won the "China Green Efficiency Enterprise-Green Responsibility Award" at the 6th World Environmental Protection Conference.
2. China Resources Sanjiu entered the list of 222 Chinese A-share companies in MSCI
On June 21, China Resources Sanjiu (000999) entered the list of 222 Chinese A-share companies in MSCI, which is a recognition of the overall strength and value of listed companies.
3. Ganmaoling granules/capsules ranked No. 1 in the comprehensive statistical ranking of non-prescription drug products in China (Chinese patent medicine) in the cold and cough category
On December 9, 999 Ganmaoling Granules/Capsules once again won the first place in the “Comprehensive Statistical Ranking of Non-prescription Drug Products in China (Chinese Proprietary Medicine)” in the cold and cough category, winning this honor for eight consecutive years. In addition, 13 varieties of China Resources Sanjiu were selected into the "Comprehensive Ranking of Non-prescription Drug Products in China (Chinese Patent Medicine/Chemical Medicine) List".
【Merger and Acquisition Integration】
1. China Resources Sanjiu acquired 65% equity of Shandong Shenghai to help the development of big health business
On September 13, China Resources Sanjiu officially acquired a 65% stake in Shandong Shenghai. It will help China Resources Sanjiu quickly supplement the categories and varieties of mainstream health care products and build a foundation for the development of the big health business. Shandong Shenghai's good health care product supply chain foundation will help the rapid growth of China Resources Sanjiu's major health business.
2. China Resources Sanjiu acquired 65% equity of Jinfukang Pharmaceutical Co., Ltd. to enrich the anti-tumor product line
On January 17, China Resources Sanjiu acquired a 65% stake in Jilin Jinfukang Pharmaceutical Co., Ltd. ("Jinfukang Pharmaceutical") held by Jilin Donglang Pharmaceutical Co., Ltd. ("Donglang Pharmaceutical"). Further enrich the anti-tumor product line, give full play to the core advantages, and implement the company's business development strategy.
【innovating】
1. The related research project of "Li Wei Wang" won the first prize of Science and Technology Award of China Association of Traditional Chinese Medicine
In March, in the 2016 China Association of Traditional Chinese Medicine Science and Technology Award review, the Institute of Medicinal Plants, Chinese Academy of Medical Sciences was the lead unit, and Kunming Shenghuo Pharmaceuticals was the research project of the participating unit——"Comprehensive Development of Large Varieties of Chinese Medicine Notoginseng Key Technology Creation and Industrialization Application" won the first prize and was voted unanimously, ranking first.
2. "Haowawa Children's Medicine and Health Products Research Center" was established
On December 30, "Haowawa Children's Medicine and Health Products Research Center" was officially established in Sunstone (Tangshan) Pharmaceutical Co., Ltd. This is a new starting point for the development of China Resources Sanjiu's pediatric products, which will effectively promote the development of Sunstone Pharmaceuticals and the upgrade of the Haowall brand.
【governmental support】
1. China Resources Sanjiu participated in the construction of the Sinopharm Seed Seedling Breeding Base and passed the acceptance
On December 1, the Ya'an main base of the national essential medicine seedling breeding (Sichuan) base successfully passed the on-site acceptance of the State Administration of Traditional Chinese Medicine.
The Ya'an main base of the base is jointly established by the Sichuan Academy of Traditional Chinese Medicine, China Resources Sanjiu (Ya'an) Pharmaceutical Co., Ltd. and the Ya'an Municipal People's Government. Breeding technology research and production demonstration and promotion base.
【business development】
1. China Resources Sanjiu formally established the Great Health Division
On the morning of March 7, the business start-up meeting of China Resources Sanjiu Health Division was held. At the meeting, a special start-up ceremony was held. A total of more than 120 people from the company's management and representatives from various departments gathered together to witness the new and promising journey of the Great Health Division.
2. China Resources Sanjiu's fifth-generation cephalosporin antibiotic project settled in Xinmin, Liaoning
On December 19, Xinmin Municipal Government of Liaoning Province and China Resources Jiuxin Pharmaceutical Co., Ltd., a subsidiary of China Resources Sanjiu, signed a cooperation agreement on the production and settlement of its patented product, the fifth-generation cephalosporin antibiotic (cefabiroxetil). The project settled in Shenyang Sanjiu Pharmaceutical Co., Ltd. located in Xinmin Economic Development Zone. After completion, Shenyang Sanjiu Pharmaceutical Co., Ltd. will become the only supplier of the fifth-generation cephalosporin in mainland China.
【Important item】
1. China Resources Sanjiu signed a contract with Hubei Provincial Hospital of Traditional Chinese Medicine on the "Investment and Operation Cooperation Project of Preparation Center in Wudong Campus"
New progress has been made in the strategic cooperation between China Resources Sanjiu Pharmaceutical Co., Ltd. and Hubei Provincial Hospital of Traditional Chinese Medicine. On June 23, the cooperation project of "Investment and Operation of Preparation Center Construction in Wudong Campus" was signed.
2. China Resources Sanjiu signed a strategic framework agreement with Hebei Provincial Hospital of Traditional Chinese Medicine
On August 23, China Resources Sanjiu Pharmaceutical Co., Ltd. signed a strategic framework agreement with Hebei Provincial Hospital of Traditional Chinese Medicine. The two parties will work together to vigorously promote the "Innovative Development of Traditional Chinese Medicine" project.
3. China Resources Sanjiu signed a contract with Anhui University of Traditional Chinese Medicine on the "Industry-University-Research Cooperation Project"
On September 30, China Resources Sanjiu Pharmaceutical Co., Ltd. signed a strategic framework agreement and a scholarship project cooperation agreement with Anhui University of Traditional Chinese Medicine.
【Foreign Cooperation】
1. The cooperation project between China Resources Sanjiu and Sanofi is progressing smoothly
On June 10, Jiao Yanlong, secretary of the Tangshan Municipal Party Committee, visited Sunstone (Tangshan) Pharmaceutical Co., Ltd., learned about the situation after the establishment of the joint venture company, and fully affirmed it. Sunstone Pharmaceuticals is a cooperation project between China Resources Sanjiu and Sanofi, and the cooperation between the two parties is progressing smoothly. At the same time, Yishanfu, the global leading brand of liver-protecting OTC drugs, was handed over smoothly, and the hospital market and retail market achieved expected growth.
2. China Resources Jiuxin and Switzerland's Basilea reached a technology authorization agreement for the fifth generation of cephalosporin antibiotics
On September 28, Shenzhen China Resources Jiuxin Pharmaceutical Co., Ltd. signed an agreement with Basilea Pharmaceutica International Ltd (BSLN), a Swiss listed company, to reach an agreement in mainland China and Hong Kong for the fifth-generation cephalosporin antibiotic (cefebiroxil) under the patent of Basilea. , Macau's exclusive technology authorization cooperation.